drugset
drugset / Trial / NCT04950530

The Effect of Biktarvy (B/F/TAF) on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers

NCT04950530 ↗

Phase 1 Completed 25 enrolled Chelsea and Westminster NHS Foundation Trust
RandomizedCrossoverOpen-labelTreatment

Summary

This study will investigate changes in insulin sensitivity, lipid metabolism and endocrine profile in HIV-negative subjects exposed to Biktarvy (B/F/TAF) compared to subject not exposed to B/F/TAF for 28 days.

Timeline

Start
2022-12-22
Primary completion
2024-02-29
Completion
2024-02-29

Drugs

EvaluationDrugModalityDoseRoute
Subject bictegravir Small molecule 50 mg Oral
Subject emtricitabine Other / unclassified 200 mg Oral
Subject tenofovir alafenamide Small molecule 25 mg Oral

Indications

HIV infectious disease